Baltimore, MDNCT07851025Now EnrollingIRB Ready

Epithelial Ovarian Cancer Clinical Trial in Baltimore, MD

Access cutting-edge epithelial ovarian cancer treatment through this phase 3 clinical trial at a research site in Baltimore. Study-provided care at no cost to qualified participants.

Sponsored by AstraZeneca

Quick Self-Assessment

See if you qualify for this Baltimore location

Preparing your pre-screening questions…

Expert Care in Baltimore

Access epithelial ovarian cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related epithelial ovarian cancer treatment provided free

Apply for This Baltimore Location

Check if you qualify for this epithelial ovarian cancer clinical trial in Baltimore, MD

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Baltimore

    Convenient for MD residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Baltimore site if eligible
  4. 4Begin participation

About This Epithelial Ovarian Cancer Study in Baltimore

This study will evaluate the efficacy, safety and tolerability of Torvutatug samrotecan (torvu-sam) in combination with bevacizumab compared with bevacizumab monotherapy as first line maintenance treatment in patients with Homologous Recombination Deficient (HRD) negative advanced ovarian cancer.

Sponsor: AstraZeneca

Who Can Participate

Inclusion Criteria

Participants with newly diagnosed FIGO Stage III/IV, histologically confirmed epithelial high-grade ovarian, fallopian tube or primary peritoneal carcinoma
Provision of an archival FFPE tumour sample
Participants who have completed at least 6 cycles and a maximum of 8 cycles of first-line Platinum-based chemotherapy (PBC) prior to randomisation
Participants must have received a minimum of 3 cycles of bevacizumab in combination with the 3 last cycles of PBC, prior to randomisation
Participants who have completed cytoreductive surgery or have inoperable disease
Participants with non-progressive disease upon completion of front-line induction therapy
HRD negative tumour Key

Exclusion Criteria

Participants with tumours of non-epithelial origin, borderline tumours, or low-grade epithelial tumours.
Participants with history of (non-infectious) ILD/pneumonitis that required steroids or supplemental oxygen, or has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at Screening
Participants with non-healing wound, active ulcer, or bone fracture
Participants with evidence of active or ongoing bowel obstruction
Prior exposure to any FRα-targeted therapy, including MIRV, or any TOP1i Antibody-drug Conjugate (ADC)

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Baltimore?

Yes, this clinical trial (NCT07851025) has an active research site in Baltimore, MD that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Epithelial Ovarian Cancer Treatment Options in Baltimore, MD

If you're searching for epithelial ovarian cancer treatment options in Baltimore, MD, this clinical trial (NCT07851025) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Baltimore research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced epithelial ovarian cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all epithelial ovarian cancer clinical trials near you to find additional studies recruiting in your area.

More Ovarian Cancer Trials in Baltimore, MD

See all ovarian cancer clinical trials recruiting in Baltimore — not just this study.

Browse Ovarian Cancer Trials in Baltimore →

Browse More Trials by Condition

Ovarian Cancer TrialsAll Conditions →

Ready to Join in Baltimore?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Baltimore, MD